论文信息 - Are We Getting the Best Return on Investment From Clinical Drug‐Drug Interaction Studies?

Are We Getting the Best Return on Investment From Clinical Drug‐Drug Interaction Studies?

Atlanta, GA. 9. Somani AA, Lagishetty CV, Bartolome L, Lesko LJ. Evaluation of pharmacokinetic drug-drug interaction studies information for FDA approved drugs for the year 2004, 2012 and 2013. American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2015 late-breaking poster abstract, New Orleans,

L. Lesko | Chakradhar Lagishetty

[1] A. Galetin,et al. ITC Commentary on the Prediction of Digoxin Clinical Drug–Drug Interactions from In Vitro Transporter Assays , 2014, Clinical pharmacology and therapeutics.

[2] D J Greenblatt,et al. In Vitro Prediction of Clinical Drug Interactions With CYP3A Substrates: We Are Not There Yet , 2014, Clinical pharmacology and therapeutics.

[3] M. Ratain,et al. Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs , 2013, Clinical Cancer Research.

[4] P. Sager,et al. The Cardiac Safety Research Consortium electrocardiogram warehouse: thorough QT database specifications and principles of use for algorithm development and testing. , 2010, American heart journal.

[5] Caroline A. Lee,et al. Drug–Drug Interactions Mediated Through P‐Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug , 2009, Clinical pharmacology and therapeutics.

[6] Shiew-Mei Huang,et al. Assessment of the Quality and Quantity of Drug‐Drug Interaction Studies in Recent NDA Submissions: Study Design and Data Analysis Issues , 1999, Journal of clinical pharmacology.

[7] A. D. Rodrigues,et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir , 1997, Antimicrobial agents and chemotherapy.